Загрузка...
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
BACKGROUND: Several cancer types harbor alterations in the gene encoding AT-Rich Interactive Domain-containing protein 1A (ARID1A), but there are no approved therapies to address these alterations. Recent studies have shown that ARID1A deficiency compromises mismatch repair proteins. Herein, we anal...
Сохранить в:
| Опубликовано в: : | J Immunother Cancer |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMJ Publishing Group
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7057434/ https://ncbi.nlm.nih.gov/pubmed/32111729 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000438 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|